Novacyt Valuation

ALNOV Stock  EUR 0.58  0.01  1.69%   
Novacyt is overvalued. Novacyt secures a last-minute Real Value of €0.56 per share. The latest price of the firm is €0.58. Our model forecasts the value of Novacyt from analyzing the firm fundamentals such as Current Valuation of (48.03 M), return on equity of -0.0198, and Profit Margin of (0.1) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
0.58
Please note that Novacyt's price fluctuation is out of control at this time. Calculation of the real value of Novacyt is based on 3 months time horizon. Increasing Novacyt's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Novacyt's intrinsic value may or may not be the same as its current market price of 0.58, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  0.58 Real  0.56 Hype  0.58 Naive  0.53
The intrinsic value of Novacyt's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novacyt's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
0.56
Real Value
6.01
Upside
Estimating the potential upside or downside of Novacyt helps investors to forecast how Novacyt stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novacyt more accurately as focusing exclusively on Novacyt's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.560.640.71
Details
Hype
Prediction
LowEstimatedHigh
0.030.586.03
Details
Naive
Forecast
LowNext ValueHigh
0.010.535.98
Details

Novacyt Total Value Analysis

Novacyt is presently projected to have takeover price of (48.03 M) with market capitalization of 48.96 M, debt of 1.45 M, and cash on hands of 101.75 M. The negative valuation of Novacyt may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should thoroughly investigate all of the Novacyt fundamentals.
  Takeover PriceMarket CapDebt ObligationsCash
(48.03 M)
48.96 M
1.45 M
101.75 M

Novacyt Investor Information

The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. Novacyt recorded a loss per share of 0.04. The entity had not issued any dividends in recent years. Based on the key indicators related to Novacyt's liquidity, profitability, solvency, and operating efficiency, Novacyt is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.

Novacyt Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novacyt has an asset utilization ratio of 52.14 percent. This connotes that the Company is making €0.52 for each dollar of assets. An increasing asset utilization means that Novacyt is more efficient with each dollar of assets it utilizes for everyday operations.

Novacyt Ownership Allocation

Novacyt maintains a total of 70.63 Million outstanding shares. Novacyt secures 3.49 % of its outstanding shares held by insiders and 1.6 % owned by institutional investors. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Novacyt Profitability Analysis

The company reported the revenue of 95.78 M. Net Loss for the year was (9.73 M) with profit before overhead, payroll, taxes, and interest of 64.87 M.

About Novacyt Valuation

The stock valuation mechanism determines Novacyt's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Novacyt based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novacyt. We calculate exposure to Novacyt's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novacyt's related companies.
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people.

8 Steps to conduct Novacyt's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Novacyt's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Novacyt's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Novacyt's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Novacyt's revenue streams: Identify Novacyt's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Novacyt's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Novacyt's growth potential: Evaluate Novacyt's management, business model, and growth potential.
  • Determine Novacyt's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Novacyt's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Additional Tools for Novacyt Stock Analysis

When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.